The market has climbed 1.8% in the last 7 days and is up 9.5% over the last 12 months, with earnings expected to grow by 14% per annum over the next few years. In such a climate, identifying stocks with strong fundamentals can be key to uncovering hidden value. Though often seen as a relic of past trading days, penny stocks—typically representing smaller or newer companies—still offer potential for significant returns when backed by solid financials.

Top 10 Penny Stocks In The United States

Click here to see the full list of 750 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Lexeo Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company addressing hereditary and acquired diseases with high unmet need in the United States, with a market cap of approximately $130.46 million.

Operations: Lexeo Therapeutics, Inc. currently has no reported revenue segments.

Market Cap: $130.46M

Lexeo Therapeutics, with a market cap of US$130.46 million, remains pre-revenue but has shown promising clinical progress. Recent positive interim data from its LX2006 trials for Friedreich ataxia cardiomyopathy supports advancement to a registrational study by early 2026. Despite being debt-free and having short-term assets exceeding liabilities, the company's cash runway is limited to just over a year if current cash flow trends persist. While losses have increased over the past five years, Lexeo's management is relatively new and earnings are forecasted to decline further in the near term.

• Get an in-depth perspective on Lexeo Therapeutics' performance by reading our balance sheet health report here.
• Learn about Lexeo Therapeutics' future growth trajectory here.

Oil States International

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Oil States International, Inc. operates globally through its subsidiaries, offering engineered capital equipment and consumable products for the energy, industrial, and military sectors with a market cap of approximately $217.68 million.

Operations: No specific revenue segments are reported for Oil States International, Inc.

Market Cap: $217.68M

Oil States International, with a market cap of US$217.68 million, has demonstrated financial resilience despite being unprofitable. The company reported first-quarter revenue of US$159.94 million and a net income of US$3.16 million, marking an improvement from the previous year's loss. Its short-term assets significantly exceed both short- and long-term liabilities, ensuring liquidity stability. While its share price remains highly volatile and the return on equity is negative at -1.65%, Oil States maintains a satisfactory net debt to equity ratio of 8.8%. Recent management changes include appointing Deloitte & Touche LLP as auditors for fiscal year 2025.

• Jump into the full analysis health report here for a deeper understanding of Oil States International.
• Assess Oil States International's previous results with our detailed historical performance reports.

Tecogen

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Tecogen Inc. designs, manufactures, markets, and maintains cogeneration products for various sectors in the United States and has a market capitalization of $61.71 million.

Operations: The company's revenue is derived from three segments: Products ($4.44 million), Services ($16.07 million), and Energy Production ($2.10 million).

Market Cap: $61.71M

Tecogen Inc., with a market cap of US$61.71 million, operates in the cogeneration sector and faces challenges typical of penny stocks. Although unprofitable, it maintains a solid financial position with short-term assets exceeding both short- and long-term liabilities, and more cash than total debt. Recent earnings showed a slight revenue decline to US$22.62 million for 2024, alongside an increased net loss of US$4.76 million. The company has filed for a shelf registration to raise approximately US$5.92 million through common stock offerings related to its ESOP plan, indicating potential future capital raising efforts amidst its volatile share price environment.

• Unlock comprehensive insights into our analysis of Tecogen stock in this financial health report.
• Understand Tecogen's track record by examining our performance history report.

Key Takeaways

• Navigate through the entire inventory of 750 US Penny Stocks here.
• Looking For Alternative Opportunities? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:LXEO NYSE:OIS and OTCPK:TGEN.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com